EUVIMEDEUVIMED entdecken
Crossref

Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors

Madeline L O'Sullivan, Grant W Cannon iD, Brian C Sauer iD, Jorge Rojas, Gary A Kunkel, Jessica A Walsh iD, Shardool Patel, Punyasha Roul, Joshua F Baker, Bryant R England iD, Ted R Mikuls iD, Tawnie J Braaten

Arthritis Care & Research · 2026

DOI: 10.1002/acr.25691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Madeline L O'Sullivan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Salt Lake City VA and University of Utah. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Immune Checkpoint Inhibitors, Veterans, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NIH HHS, U.S. Department of Veterans Affairs, CSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This investigation compared all‐cause and cause‐specific mortality in patients with and without rheumatoid arthritis (RA) in the Veterans Health Administration (VHA) following immune checkpoint inhibitor (ICI) cancer treatment.

Methods

Veterans with RA and a control set of Veterans without RA who were matched on age, sex, and year of Veterans Affairs enrollment and had received an ICI were identified. All‐cause and cause‐specific mortality were obtained. Survival from the time of ICI initiation was evaluated using Cox models, Kaplan‐Meier curves, and log rank testing.

Results

There were 301 patients with RA and 2,114 controls without RA treated with an ICI. The majority of the participants were white, male, and current/former smokers. Lung cancer was the most common malignancy (51.2%), pembrolizumab was the most frequently used ICI (43.9%), and most patients received ICI monotherapy (97.1%). Cox proportional hazard ratio comparison of all‐cause mortality in patients with RA to controls without RA was 1.08 (95% confidence interval [CI] 0.94–1.25) for the crude analysis and 1.09 (95% CI 0.94–1.25) for the adjusted analysis. Cause of death was similar in the two groups, most frequently neoplasm in 93.0% and 90.9% for RA and non‐RA groups, respectively ( P = 0.737). Deaths due to infection were rare in both groups (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidImmune Checkpoint InhibitorsVeteransNeoplasmsHumansMaleFemaleAgedMiddle AgedUnited StatesCause of DeathVeterans HealthRetrospective StudiesCase-Control StudiesRisk FactorsUnited States Department of Veterans Affairs

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Salt Lake City VA and University of Utah.
  • Puget Sound VA Medical Center, Seattle, Washington.
  • University of Utah, Salt Lake City.
  • VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha.
  • Corporal Michael J. Crescenz VA and University of Pennsylvania, Philadelphia.

ORCID-Profile: Grant W Cannon, Brian C Sauer, Jessica A Walsh, Bryant R England, Ted R Mikuls

Förderung

  • NIH HHS
  • U.S. Department of Veterans Affairs
  • CSRD VA
  • U.S. Department of Defense
  • Western Institute for Veterans Research
  • National Institutes of Health

Zitieren

APA

O'Sullivan, M. L., Cannon, G. W., Sauer, B. C., Rojas, J., Kunkel, G. A., Walsh, J. A., Patel, S., Roul, P., Baker, J. F., England, B. R., Mikuls, T. R., & Braaten, T. J. (2026). Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors. Arthritis Care & Research. https://doi.org/10.1002/acr.25691

Vancouver

O'Sullivan ML, Cannon GW, Sauer BC, Rojas J, Kunkel GA, Walsh JA, et al. Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors. Arthritis Care & Research. 2026. doi:10.1002/acr.25691

BibTeX
@article{OSullivan2026,
  author = {O'Sullivan, Madeline L and Cannon, Grant W and Sauer, Brian C and Rojas, Jorge and Kunkel, Gary A and Walsh, Jessica A and Patel, Shardool and Roul, Punyasha and Baker, Joshua F and England, Bryant R and Mikuls, Ted R and Braaten, Tawnie J},
  title = {Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors},
  journal = {Arthritis Care & Research},
  year = {2026},
  doi = {10.1002/acr.25691}
}
Kostenlos starten →